Year: 2010
Type: article
Abstract: Iatrogenic hypoglycemia is a problem for people affected by diabetes (1). It causes recurrent morbidity in most people with type 1 diabetes and many with advanced type 2 diabetes, and it is sometimes fatal. It generally precludes maintenance of euglycemia over a lifetime of diabetes and thus full realization of the vascular benefits of glycemic control. And, it compromises defenses against subsequent falling plasma glucose concentrations and therefore causes a vicious cycle of recurrent hypoglycemia. Hypoglycemia in diabetes is fundamentally iatrogenic, the result of therapeutic hyperinsulinemia caused by treatment with a sulfonylurea, a glinide, or insulin. But because of the effectiveness of the normal glucose counterregulatory mechanisms, hypoglycemia is typically the result
Source: Diabetes
DOI: 10.2337/db10-1359
Author: Philip E. Cryer
Institution: Washington University in St. Louis
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: American Diabetes Association, Bristol-Myers Squibb, AstraZeneca, MannKind Corporation, Novo Nordisk, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Research Resources, National Center for Advancing Translational Sciences
OpenAlex ID: W2126453854
